drugset / Trial / NCT01813318
Study of Acamprosate in Autism
RandomizedParallel-groupQuadruple-blindBasic science
Summary
Recent pharmacotherapy research in autism spectrum disorders (ASD) has successfully focused on treatment of co-occurring symptoms, including inattention, hyperactivity, and irritability that commonly occur in persons with ASD. Despite over two decades of significant pharmacotherapy research, to date no medication has been shown in controlled trials to enhance the core social deficits of ASD. Based upon findings describing the neurobiology of ASD combined with our preliminary results, we believe the novel drug acamprosate will show evidence of reducing social skills deficits associated with ASD.
Timeline
- Start
- 2013-07-02
- Primary completion
- 2017-09-07
- Completion
- 2017-09-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Acamprosate | Small molecule | 1332 mg | — |
| Comparator | Acamprosate | Small molecule | 1998 mg | — |